The FDA rounded out the month with the approval of remibrutinib (Rhapside; Novartis), a highly selective Bruton tyrosine kinase inhibitor (BTKi), for patients with chronic spontaneous urticaria (CSU) ...
Preliminary analysis of one-year progression-free survival data from Phase 2 study of novel SST2 agonist paltusotine under ...
Pharmaceuticals announced three abstracts from its clinical development programs will be presented at the upcoming North American ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback